Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

Cardiac, renal, and metabolic effects of sodium–glucose co-transporter 2 inhibitors: a position paper from the European Society of Cardiology ad-hoc task force on sodium–glucose co-transporter 2 inhibitors

In 2015, the first large-scale placebo-controlled trial designed to assess cardiovascular safety of glucose-lowering with sodium–glucose co-transporter 2 (SGLT2) inhibition in type 2 diabetes mellitus raised hypotheses that the class could favourably modify not only risk of atherosclerotic cardiovas...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí:	Herrington, WG, Savarese, G, Haynes, R, Marx, N, Mellbin, L, Lund, LH, Dendale, P, Seferovic, P, Rosano, G, Staplin, N, Baigent, C, Cosentino, F
Formáid:	Journal article
Teanga:	English
Foilsithe / Cruthaithe:	Wiley 2021

Míreanna comhchosúla

Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
de réir: Giuseppe Rosano, et al.
Foilsithe / Cruthaithe: (2020-11-01)

Effect of sodium-glucose Co-transporter 2 inhibitors on coronary microcirculation
de réir: Shaoxin Chen, et al.
Foilsithe / Cruthaithe: (2025-02-01)

Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
de réir: Moran Gvili Perelman, et al.
Foilsithe / Cruthaithe: (2024-01-01)

Impact of diabetes on the effects of sodium glucose co-transporter-2 (SGLT2) inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials
de réir: Herrington, W, et al.
Foilsithe / Cruthaithe: (2022)

Current developments in peritoneal glucose transport and sodium-glucose co-transporter 2 inhibitors during peritoneal dialysis
de réir: Fan Yang, et al.
Foilsithe / Cruthaithe: (2023-11-01)

Efficacy of sodium-glucose co-transporter-2 inhibitors in patients with heart failure
de réir: E. V. Kovalenko, et al.
Foilsithe / Cruthaithe: (2021-02-01)

The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis
de réir: Panagiotis Stachteas, et al.
Foilsithe / Cruthaithe: (2023-12-01)

Sodium-glucose co-transporter-2 inhibitor-associated non-diabetic ketoacidosis: a case report
de réir: Vincenzo Trapanese, et al.
Foilsithe / Cruthaithe: (2024-04-01)

Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials
de réir: Staplin, N, et al.
Foilsithe / Cruthaithe: (2021)

Impact of Sodium‐Glucose Co‐Transporter‐2 Inhibitors on Exercise‐Induced Pulmonary Hypertension
de réir: Taijyu Satoh, et al.
Foilsithe / Cruthaithe: (2024-10-01)

Myeloproliferative Neoplasms and Sodium-Glucose Co-Transporter-2 Inhibitors: A Case Series
de réir: Pusem Patır, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Advances in sodium-glucose transporter protein 2 inhibitors and tumors
de réir: Jiaqi Wang, et al.
Foilsithe / Cruthaithe: (2025-02-01)

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy
de réir: Bray, JJ, et al.
Foilsithe / Cruthaithe: (2024)

The effect of sodium‐glucose co‐transporter 2 inhibitors on outcomes after cardiac resynchronization therapy
de réir: Jonathan J.H. Bray, et al.
Foilsithe / Cruthaithe: (2024-08-01)

Individual Approach to Prescribing Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Hypertrophic Cardiomyopathy
de réir: Vira Y. Tseluyko, et al.
Foilsithe / Cruthaithe: (2024-03-01)

Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials
de réir: Vale, C, et al.
Foilsithe / Cruthaithe: (2024)

Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
de réir: Hinton, W, et al.
Foilsithe / Cruthaithe: (2020)

Effects of sodium‐glucose co‐transporter‐2 inhibitors in type 2 diabetes in women versus men
de réir: Rådholm, K, et al.
Foilsithe / Cruthaithe: (2019)

Effects of Sodium–Glucose Co-Transporter 2 Inhibitors on Serum Chloride Concentrations in Patients with Heart Failure
de réir: Ivana Jurin, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Metabolic reprogramming as the basis for sodium-glucose co-transporter type 2 inhibitors cardio- and nephroprotective effect
de réir: O N. Kurochkina, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Real-world effectiveness and safety of sodium-glucose co-transporter 2 inhibitors in chronic kidney disease
de réir: Supattra Hunsuwan, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Sodium-glucose co-transporter-2 inhibitors in heart failure and chronic kidney disease: the role of empagliflozin
de réir: M. M. Batyushin
Foilsithe / Cruthaithe: (2021-04-01)

Sodium-glucose co-transporter 2 inhibitors: a pleiotropic drug in humans with promising results in cats
de réir: Aline B. Vieira, et al.
Foilsithe / Cruthaithe: (2025-02-01)

The clinical cases of ketoacidosis in patients with 2 type diabetes treated with inhibitors of sodium-glucose co-transporter
de réir: Diana Sh. Avzaletdinova, et al.
Foilsithe / Cruthaithe: (2021-09-01)

Sodium-Glucose Linked Transporter-2 Inhibitors in Chronic Kidney Disease
de réir: L. Zanoli, et al.
Foilsithe / Cruthaithe: (2015-01-01)

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study
de réir: Herrington, W, et al.
Foilsithe / Cruthaithe: (2018)

Sodium-glucose co-transporter 2 (SGLT2) inhibitor: comparing trial data and real-world use
de réir: McGovern, A, et al.
Foilsithe / Cruthaithe: (2017)

Incidental changes in hemoglobin levels in patients with myelofibrosis receiving treatment with sodium-glucose co-transporter-2 inhibitors
de réir: Fnu Aperna, et al.
Foilsithe / Cruthaithe: (2024-11-01)

Sodium glucose co-transporter 2 inhibitors (SGLT2i) for pediatric kidney disease: the future is near
de réir: Gilda M. Portalatin, et al.
Foilsithe / Cruthaithe: (2025-01-01)

Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
de réir: Ja Young Jeon, et al.
Foilsithe / Cruthaithe: (2024-09-01)

Sodium–glucose co-transporter-2 inhibitors - empagliflozin and dapagliflozin as future therapy for Alport Syndrome, literature review
de réir: Magdalena Kłusek, et al.
Foilsithe / Cruthaithe: (2024-07-01)

Sodium-Glucose Co-Transporter 2 (SGLT-2) Inhibitors in Heart Failure: A Comprehensive Review of Literature
de réir: Asfandyar Khattak, et al.
Foilsithe / Cruthaithe: (2024-04-01)

The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
de réir: Muhammad Usman Ali, et al.
Foilsithe / Cruthaithe: (2024-02-01)

Sodium-Glucose Transport Protein 2 Inhibitors Association with Euglycemic Diabetic Ketoacidosis
de réir: Caroline Wojtas, et al.
Foilsithe / Cruthaithe: (2023-01-01)

Sodium–Glucose Transporter 2 Inhibitors in Heart Failure: An Overview of Systematic Reviews
de réir: Yixuan Fang, et al.
Foilsithe / Cruthaithe: (2024-06-01)

Effects of sodium-glucose cotransporter 2 inhibitors on cause-specific cardiovascular death in patients with CKD
de réir: Fletcher, RA, et al.
Foilsithe / Cruthaithe: (2024)

Sodium-glucose co-transporter-2 (SGLT2) inhibitors: comparing trial and real world use (study protocol)
de réir: McGovern, A, et al.
Foilsithe / Cruthaithe: (2017)

When Should We Start Sodium–Glucose Co-transporter Inhibitors in Patients with Heart Failure? The Importance of Early Intervention
de réir: Moritake Iguchi, et al.
Foilsithe / Cruthaithe: (2023-06-01)

A New Chapter in the Treatment of Patients with Heart Failure. The Role of Sodium-Glucose Co-transporter Type 2 Inhibitors
de réir: D. P. Golubovskaya, et al.
Foilsithe / Cruthaithe: (2022-11-01)

Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
de réir: Kris Aubrey-Bassler, et al.
Foilsithe / Cruthaithe: (2019-02-01)